Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF in locally advanced head and neck squamous cell carcinoma: a study of 48 patients-Reference-Cited by-同舟云学术

Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF in locally advanced head and neck squamous cell carcinoma: a study of 48 patients

Published:2016-04-22 Issue:24 Volume:7 Page:37297-37304
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Fayette Jérôme¹,Fontaine-Delaruelle Clara¹,Ambrun Alexis²,Daveau Clémentine³,Poupart Marc²,Ramade Antoine³,Zrounba Philippe⁴,Neidhardt Eve-Marie¹,Péron Julien⁵⁶,Diallo Alpha⁷,Céruse Philippe³⁷

Affiliation:

1. Department of Medicine, Léon Bérard Center, University of Lyon, Lyon, France

2. Department of Surgery, Croix-Rousse Hospital, University of Lyon, Lyon, France

3. Department of Surgery, Edouard Herriot Hospital, University of Lyon, Lyon, France

4. Department of Surgery, Léon Bérard Center, University of Lyon, Lyon, France

5. Department of Medical Oncology, Institut du Cancer des Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, University of Lyon, Pierre-Bénite, France

6. CNRS-UMR 5558, Biometry and Evolutive Biology Laboratory, Health and Biostatistics Team, Villeurbanne, France

7. Department of Surgery, Lyon Sud Hospital Center, University of Lyon, Pierre-Bénite, France

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Indian clinical practice consensus guidelines for the management of oropharyngeal cancer: Update 2022;Cancer Research, Statistics, and Treatment;2024

2. Indian clinical practice consensus guidelines for the management of hypopharyngeal cancer: Update 2022;Cancer Research, Statistics, and Treatment;2024

3. Taxanes in the Treatment of Head and Neck Squamous Cell Carcinoma;Biomedicines;2023-10-25

4. Induction chemotherapy in locally advanced head and neck cancers, is there a best choice?;Critical Reviews in Oncology/Hematology;2023-06

5. Suppression of TLR signaling by IRAK-1 and -4 dual inhibitor decreases TPF-resistance-induced pro-oncogenic effects in HNSCC;3 Biotech;2022-12-17